In 2020, the COVID-19 pandemic had a significant impact on many areas of society. However, drug approvals in the pharma industry was not adversely impacted, and despite staffing issues the FDA was able to approve 121 novel drugs in 2020
The COVID-19 pandemic’s impacts were numerous and far-reaching, creating disruptions across the world. However, new pharmaceutical product launches continued, leading to the development of vaccines and many other products. How have Clinical Trials Been Impacted by the Pandemic? Clinical trials have faced
Matrix Healthcare Solutions (MHS) has further complimented its expansive licensed capabilities with the addition of a Manufacturers Import Authorisation (MIA) for Investigational Medicinal Products (IMP). The stringent controls and high standards required for IMP management in clinical trials have a direct impact on product registration with regulatory and competent authorities around the world. The MIA (IMP) allows Matrix Healthcare Solutions to better serve its increasing global base of customers.
Matrix Healthcare Solutions is delighted to announce we have been granted direct access to medicines from Pfizer limited, for the purposes of supplying third party clinical trials, this covers access to the full UK / EU licenced portfolio of 453 lines. The Pfizer portfolio includes a number of oncology, antibacterial, and biologic medicines.
Biological products, also known as biologics, have formed a cornerstone of modern healthcare for decades. Blood transfusions, gene therapy, monoclonal antibody treatment, vaccinations, and many more key clinical processes rely on goods derived from living organisms rather than chemical synthesis.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has released its 2020-21 business plan, outlining its primary goals for the coming year. Driven by the need to develop new regulatory models and improving patient access to cutting-edge drugs and medical
Matrix Healthcare Solutions further expands licensed capabilities with the addition of Manufacturer’s “Specials” (MS) license.
Various news outlets around the world have reported on apparent clinical trials testing the efficacy of anti-HIV (human immunodeficiency viruses) medication in combatting COVID-19.
Zac has focused his career in the pharmaceutical industry, sourcing comparative medicines for use in a wide category of Clinical Trials.